BRIEF-Pfizer presents results from Phase 2 study of investigational ALK-inhibitor lorlatinib
October 16, 2017 at 07:30 AM EDT
* Pfizer presents full results from Phase 2 study of next-generation investigational ALK-inhibitor lorlatinib in ALK-positive and ROS1-positive advanced non-small cell lung cancer
